BOOKS BY CATEGORY
Your Account
Clinical Dilemmas in Non–Alcoholic Fatty Liver Disease
This book is currently unavailable – please contact us for further information.
Price
Quantity
€63.99
(To see other currencies, click on price)
Other digital
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Clinical Dilemmas in Non–Alcoholic Fatty Liver Disease offers hepatologists practical, up–to–date and expert guidance on the most topical dilemmas, difficulties and areas of controversy/difficulty surrounding this ever–increasing area of liver disease they face in daily practice. 


Roger Williams and Simon Taylor–Robinson, two of Europe s leading hepatologists, have recruited leading figures from across the world to assist them, resulting in a truly international approach.  Each chapter covers a specific area of difficulty, containing clear learning points and providing evidence–based expert guidance on the latest hot topics in clinical management such as:



  • Is NAFLD different in absence of Metabolic Syndrome?

  • Are the pros outweighed by the cons of obtaining a liver biopsy?

  • Is progression to cirrhosis more likely in children with NAFLD?

  • What are the dangers as well as the true benefits of bariatric surgery?

  • How is it best to use antifibrotic agents in clinical practice?


Clinical Dilemmas in Non–Alcoholic Fatty Liver Disease provides the answers to the questions and challenges that clinicians face every day in this area.  It is essential reading for hepatologists of all levels and researchers in hepatology, as well as all those involved in the care of patients with NAFLD, including gastroenterologists, pathologists and specialist hepatology nurses.


Contents:

List of contributors


Preface


Part I Nature of the condition


Chapter 1 Hype or harm from Fatty Liver Disease?
Stephen H Caldwell and Curt Argo


Chapter 2 Worldwide problem.
Geoffrey Farrell and Philip Newsome


Chapter 3  Is insulin resistance the key motive for NAFLD?
Desmond Johnston


Chapter 4 Progression to cirrhosis is more likely in children with NAFLD?
Anil Dhawan


Chapter 5 NAFLD as cause of cryptogenic cirrhosis?
Jay Lefkowitch


Chapter 6 Is NAFLD different in absence of Metabolic Syndrome?
Yusuf Yilmaz


Chapter 7 Occurrence of noncirrhotic HCC in NAFLD
Stephen Harrison and Dawn Torres


Part II Factors in Disease Progression


Chapter 8 Fibrosis progression molecular pathways all important?
Anna–Mae Diehl and Dr Wing–Kin Syn


Chapter 9 Can fatty liver of NAFLD be distinguished from that of Alcoholic Liver Disease?
David Kleiner and Elizabeth Brunt


Chapter 10 Are inflammasomes and intestinal microbiota relevant in disease progression to NASH?
M. Bilal Siddiqui, M. Shadab Siddiqui and Arun Sanyal


Chapter 11 Can genetic influence in Non–Alcoholic Fatty Liver Disease be ignored?
Quentin Anstee


Chapter 12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events?
Soo Lim


Part III Diagnosis and Scoring


Chapter 13 Is there a best method for diagnosis of NAFLD?
Vlad Ratziu


Chapter 14 Choice of non–invasive blood tests and FibroScan
Massimo Pinzani and Manolis Tsocatzis


Chapter 15 Are the guidelines – AASLD, IASL, EASL and BSG of help?
Jean–François Dufour


Chapter 16 How to choose from different imaging modalities and screening techniques
Hero Hussain


Chapter 17 Are the pros outweighed by the cons of obtaining a liver biopsy?
Simon Taylor–Robinson and Jeremy Cobbold


Chapter 18 Screening for NAFLD in high risk population
Nader Lessan


Part IV Value of treatment measures


Chapter 19 Balancing calorie restriction, exercise and weight reduction
Nicholas Finer


Chapter 20 Should Physicians be prescribing, or patients self–medicating with Orlistat, Vitamin E, Vitamin D, insulin antagonist, Trental and coffee?
Brent Neuschwander–Tetri and Haripriya Maddur


Chapter 21 Does improvement in hepatic steatosis have a significant favourable effect on the Metabolic Syndrome, including diabetes?
Jukka Westerbacka


Chapter 22 What are the dangers as well as the true benefits of bariatric surgery?
Andrew Jenkinson


Chapter 23 Liver transplantation; what can it offer?
Roger Williams


Part V What does the future hold?


Chapter 24 Molecular antagonists, leptin or other hormones in supplementing environmental factors?
Jeremy Tomlinson


Chapter 25 Use of antifibrotic agents in clinical practice
Jonathan Fallowfield


Chapter 26 Better understanding of early development and material influence?
Jude Oben


Chapter 27 Defining the role of Metabolic Physician
Nicholas Finer


Index


PRODUCT DETAILS

ISBN-13: 9781118924938
Publisher: John Wiley & Sons Ltd (Wiley–Blackwell)
Publication date: February, 2016
Pages: 264
Dimensions: 152.00 x 229.00 x 15.00
Weight: 666g
Availability: Not available (reason unspecified)
Subcategories: General Practice
Related books
From the same series

CUSTOMER REVIEWS

Average Rating